Key facts
as of Sep 2026- Chorus’s last known valuation is $69.0M (Apr 2025).
- It has raised $26.0M across 1 recorded rounds; the latest was Early Stage VC ($5.5M) in Sep 2025.
- 1 institutional filer reports fund marks on Chorus across 10 filings.
- Chorus has filed 1 Form D with the SEC, most recently Jun 2026 ($5.5M sold to 22 investors).
- Status: Privately Held (backing).
PA Mark — composite indicative price
LOW confidence~$1per share
as of Sep 2026 · the exact daily mark is a member feature
Free account
See the evidence behind this price
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for Chorus
Create free account
No card required
Recorded secondary trades
No prints on record
No secondary trades in Chorus shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
1 filers · latest Jun 20261 SEC-registered fund reported 10 fair-value marks on Chorus between Jun 2025 and Jun 2026. Filer-level marks and implied $/share are available to Pro members.
Funding rounds
1 roundsAbout Chorus
Developer of an antimicrobial system designed to safely eradicate pathogens in indoor spaces. The company's technologies mitigate airborne threats and protect every breath taken, leading to major benefits in protecting people in occupied spaces, plants in indoor agriculture applications, and fresh food in cold storage applications, enabling users to breathe without the vulnerability of getting infected.
- Sector
- Information Technology
- HQ
- Marlborough, MA, United States
- Founded
- 2020
- Employees
- 19
- Website
- meetchorus.com/
- Ownership
- Privately Held (backing)